GlassScriptPhysician profile
John M Wiprud
NPI 1457373714
$7,949.86
in general payments reported to CMS, 2019-2025
38 companies · $1,183 in 2025
The $1,183 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,772 · 2020: $324 · 2021: $452 · 2022: $1,108 · 2023: $1,577 · 2024: $1,534 · 2025: $1,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,294.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,311.23 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $611.66 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $593.93 | 2019-2025 | Shingrix, Trelegy Ellipta, Bexsero |
| Pfizer INC. | $546.89 | 2019-2025 | |
| Abbvie INC. | $503.87 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Sanofi-Aventis U.S. LLC | $496.66 | 2019-2023 | |
| Abbott Laboratories | $464.22 | 2019-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $458.36 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $407.51 | 2019-2023 | |
| Lilly USA, LLC | $372.72 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $269.12 | 2021-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $251.15 | 2023-2025 | |
| Idorsia Pharmaceuticals US INC | $235.50 | 2022-2024 | Quviviq |
| Antares Pharma, INC. | $180.50 | 2024-2025 | Xyosted |
| Exact Sciences Corporation | $153.27 | 2023-2025 | Cologuard Collection Kit |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wiprud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.